Suppliers are given the opportunity to showcase their products for retail buyers at the GMDC Health, Beauty and Wellness Marketing Conference. Below, Drug Store News highlights some of the hot OTC products in the showcase this year.
Purdue Pharma on Wednesday announced that it filed a new drug application with the Food and Drug Administration to market a hydrocodone bitartrate tablet, which is formulated to incorporate abuse-deterrent technology.
End CHRONIC PAIN! Corydalis Pain Relief Herb Pack is the newest product from the oldest Eastern herbal medicine traditions. Use it for headaches, back aches, arthritic pain and even nerve problems and muscle spasms.
DSN recently launched a new microsite, DrugStoreNews.com/Pain-Management, to bring attention to a tragic side of the prescription drug abuse story — one that's not often told. The millions of Americans who live in chronic pain who already find it difficult to access the medications they need may soon find it even more difficult — because proposed changes in regulatory policy are expected to place additional hurdles on their treatment pathway.
A study from Wahl Therapeutic Massagers released Thursday found that physical aches and soreness are a real threat to travelers of all ages — 92% of adults 18 years of age and older experience physical pain while traveling.
The Drug Store News Group, the leading provider of news, information and clinical education for the retail pharmacy industry, has launched the new microsite, Drugstorenews.com/pain-management, to help bring attention to another tragic side of the prescription drug abuse story — the millions of Americans who live in chronic pain that may be unable to access the medications they need thanks to proposed changes in regulatory policy.
VR1 on Tuesday announced the availability of Ausanil, a new non-prescription homeopathic nasal spray formulated to provide rapid pain relief from severe headaches and migraines with no reported systemic side effects or adverse drug-drug interactions.
Purdue Pharma recently announced that a Phase 3 study of an investigational extended‐release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once‐daily analgesic agent experienced statistically significant reduction in pain compared with placebo.
Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.
BioElectronics, maker of consumer medical devices and drug-free pain therapies, earlier this week announced that it is participating in upcoming consumer educational events and programs as part of an international campaign to discuss alternative pain modalities.
Most people who abuse prescription opioid drugs get them for free from a friend or relative — but those at highest risk of overdose are as likely to get them from a doctor’s prescription, Centers for Disease Control researchers reported Monday in a research letter, “Sources of Prescription Opioid Pain Relievers by Frequency of Past-Year Nonmedical Use: United States, 2008-2011,” in the Journal of the American Medical Association Internal Medicine.
New research released Tuesday found that when it comes to treating pain, a growing number of consumers know how to safely use medicines with acetaminophen and to avoid accidental overdose and liver damage.
After meeting for two days earlier this week, the Food and Drug Administration's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 16-9 against changing the label of naproxen to highlight a lower cardiovascular risk profile as compared to other NSAIDs, according to published reports.